To assess immune effects of BRAF/MEK inhibition and the potential cooperativity with ICB, we implanted ABPS tumor cells subcutaneously into immune-competent C57BL/6 mice and treated them with vehicle, DT, anti-PD-1 antibody, or the combination. This evidence concerns the gene MAP2K7 and neoplasm.